

151st SESSION OF THE WHO EXECUTIVE BOARD
GENEVA, SWITZERLAND
30TH MAY 2022

Agenda Item No. : 6

Title : Report on Hosted Partnerships

Intervention Note:

Thank you, Madam Chair.

Malaysia wishes to thank WHO for the report on the hosted partnerships.

Malaysia wishes to share with the Board that we have had a very outstanding partnership between the Drugs for Neglected Diseases Initiative (DNDi) and the Foundation for Innovative New Diagnostics (FIND). This impactful partnership has generated evidence that supports policy change and has scaled up the point of care diagnosis and decentralized treatment of Hepatitis C in Malaysia. In addition to that, Ravidasvir used in combination therapy, was the first drug for Hepatitis C Virus that was developed through South-South collaboration with funding and technical support from non-profit organizations, with funding provided by the Malaysian Government. This could not have been possible without strong political will in partnership.

It is evident, as illustrated in the report that these partnerships have benefited many Member States. Ultimately, political will and support

from the government is crucial in addition to powerful effective partnerships. On that note, Malaysia takes note of this report.

Thank you Chair.

Prepared by Dr. Juliana Paul, Global Health team on 30th May 2022 based on input & comments from TSDG

Reference <https://dndi.org/press-releases/2021/first-hepatitis-c-treatment-developed-through-south-south-cooperation-registered-in-malaysia/>